|
humans |
86 |
|
hepatocellular carcinoma |
75 |
|
female |
68 |
|
male |
67 |
|
adult |
62 |
|
middle aged |
57 |
|
aged |
43 |
|
adolescent |
41 |
|
hcc |
37 |
|
cell line, tumor |
36 |
|
liver cancer |
33 |
|
prognosis |
33 |
|
animals |
31 |
|
cell proliferation |
29 |
|
immunohistochemistry |
29 |
|
carcinoma, hepatocellular - metabolism - pathology |
27 |
|
liver neoplasms - metabolism - pathology |
27 |
|
survival rate |
27 |
|
mice |
25 |
|
retrospective studies |
25 |
|
treatment outcome |
25 |
|
survival analysis |
24 |
|
hong kong - epidemiology |
23 |
|
medical sciences |
23 |
|
aged, 80 and over |
21 |
|
follow-up studies |
21 |
|
mice, nude |
21 |
|
reverse transcriptase polymerase chain reaction |
21 |
|
gene expression regulation, neoplastic |
20 |
|
hepatectomy |
20 |
|
liver transplantation |
20 |
|
time factors |
20 |
|
immunosuppressive agents - therapeutic use |
19 |
|
child |
18 |
|
hong kong |
18 |
|
neoplasm invasiveness |
18 |
|
tumor microenvironment |
18 |
|
asian continental ancestry group - genetics |
17 |
|
carcinoma, hepatocellular - genetics - metabolism |
17 |
|
cell movement |
17 |
|
genetic predisposition to disease |
17 |
|
genome-wide association study |
17 |
|
neoplasm staging |
17 |
|
neoplasm transplantation |
17 |
|
chemicals and cas registry numbers |
16 |
|
disease-free survival |
16 |
|
living donors |
16 |
|
metastasis |
16 |
|
next-generation sequencing |
16 |
|
recurrence |
16 |
|
up-regulation |
16 |
|
age factors |
15 |
|
cell differentiation |
15 |
|
child, preschool |
15 |
|
gene expression |
15 |
|
glycolysis |
15 |
|
graft survival |
15 |
|
amino acid sequence |
14 |
|
asian |
14 |
|
association |
14 |
|
beta catenin |
14 |
|
disease models, animal |
14 |
|
disease progression |
14 |
|
down-regulation |
14 |
|
infant |
14 |
|
liver neoplasms - genetics - metabolism |
14 |
|
proteomics |
14 |
|
signal transduction |
14 |
|
transfection |
14 |
|
young adult |
14 |
|
base sequence |
13 |
|
blotting, western |
13 |
|
carcinoma, hepatocellular - mortality - pathology - surgery |
13 |
|
drug therapy, combination |
13 |
|
liver - metabolism |
13 |
|
liver - pathology |
13 |
|
liver function tests |
13 |
|
liver neoplasms - mortality - pathology - surgery |
13 |
|
neoplasm metastasis |
13 |
|
biomarker |
12 |
|
cell division - physiology |
12 |
|
deleted in liver cancer 2 |
12 |
|
ephrin-a2 - genetics |
12 |
|
gene silencing |
12 |
|
incidence |
12 |
|
intercellular communication |
12 |
|
liver neoplasms - pathology - surgery |
12 |
|
lupus erythematosus, systemic - genetics |
12 |
|
molecular sequence data |
12 |
|
mutation |
12 |
|
peptidyl-prolyl-isomerase |
12 |
|
pin1 |
12 |
|
postoperative complications |
12 |
|
protein structure, tertiary |
12 |
|
signal transduction - physiology |
12 |
|
sle |
12 |
|
therapeutics |
12 |
|
trans-activators - genetics |
12 |
|
tumor markers, biological - metabolism |
12 |
|
uhrf1bp1 |
12 |
|
antigens, cd3 - genetics |
11 |
|
bilirubin - blood |
11 |
|
carcinoma, hepatocellular - etiology - genetics - metabolism |
11 |
|
case-control studies |
11 |
|
cd247 |
11 |
|
cyclin d1 - biosynthesis - genetics |
11 |
|
cytoskeletal proteins - genetics |
11 |
|
gastroenterology medical sciences |
11 |
|
gene expression profiling |
11 |
|
gwas |
11 |
|
hepatitis b |
11 |
|
hepatitis b virus |
11 |
|
hepatitis b, chronic - complications |
11 |
|
hypoxia |
11 |
|
intraoperative complications - epidemiology |
11 |
|
liver transplantation - statistics & numerical data |
11 |
|
lupus erythematosus, systemic - genetics - immunology |
11 |
|
neovascularization, pathologic |
11 |
|
peptidylprolyl isomerase - biosynthesis - genetics |
11 |
|
predictive value of tests |
11 |
|
prospective studies |
11 |
|
protein isoforms |
11 |
|
reverse transcriptase inhibitors - therapeutic use |
11 |
|
surgery |
11 |
|
systemic lupus erythematosus |
11 |
|
tissue donors |
11 |
|
tumor cells, cultured |
11 |
|
β-catenin |
11 |
|
animal experiment |
10 |
|
antigens, cd - genetics - metabolism |
10 |
|
antiviral agents - therapeutic use |
10 |
|
apoptosis |
10 |
|
apoptosis - drug effects |
10 |
|
cadaver |
10 |
|
carcinoma, hepatocellular - mortality - surgery |
10 |
|
chromosome aberrations |
10 |
|
cyclosporine - therapeutic use |
10 |
|
gene knockdown techniques |
10 |
|
gene mutation |
10 |
|
intracellular signaling peptides and proteins - genetics |
10 |
|
liver neoplasms - mortality - surgery |
10 |
|
liver transplantation - methods |
10 |
|
lupus erythematosus, systemic - enzymology - genetics |
10 |
|
mice, inbred balb c |
10 |
|
molecular biology |
10 |
|
molecular pathology |
10 |
|
multivariate analysis |
10 |
|
neutralizing antibody |
10 |
|
phenotype |
10 |
|
platelet count |
10 |
|
reoperation |
10 |
|
repressor proteins |
10 |
|
rna, messenger - analysis |
10 |
|
sequence homology, amino acid |
10 |
|
signaling |
10 |
|
sorafenib |
10 |
|
transplantation, homologous |
10 |
|
tumor suppressor proteins - genetics - metabolism |
10 |
|
alanine transaminase - blood |
9 |
|
cancer metastasis |
9 |
|
cancer stem cell |
9 |
|
carcinoma, hepatocellular - metabolism |
9 |
|
carcinoma, hepatocellular - pathology - surgery |
9 |
|
cell division |
9 |
|
cell line |
9 |
|
chronic disease |
9 |
|
dna, viral - analysis |
9 |
|
enzyme-linked immunosorbent assay |
9 |
|
genes, p53 |
9 |
|
genes, p53 - genetics |
9 |
|
hospitals, university |
9 |
|
lamivudine - therapeutic use |
9 |
|
liver - chemistry - pathology |
9 |
|
liver - metabolism - pathology |
9 |
|
liver diseases - epidemiology |
9 |
|
liver neoplasms - genetics - mortality - pathology |
9 |
|
liver neoplasms - metabolism |
9 |
|
liver resection |
9 |
|
loss of heterozygosity |
9 |
|
microsatellite repeats |
9 |
|
oligonucleotide array sequence analysis |
9 |
|
p53 |
9 |
|
polymerase chain reaction |
9 |
|
postoperative complications - epidemiology |
9 |
|
small extracellular vesicles |
9 |
|
tumor heterogeneity |
9 |
|
acute disease |
8 |
|
antigens, cd - metabolism |
8 |
|
biliary atresia - complications - surgery |
8 |
|
blood loss, surgical |
8 |
|
body weight |
8 |
|
cancer |
8 |
|
carcinogenesis |
8 |
|
carcinogenicity tests |
8 |
|
carrier proteins - metabolism |
8 |
|
cell cycle proteins - genetics |
8 |
|
chemokine cxcl1 - physiology |
8 |
|
chromosome 8p |
8 |
|
complications of liver transplantation |
8 |
|
cyclin a2 |
8 |
|
cyclin-dependent kinase inhibitor p16 - genetics - metabolism |
8 |
|
dna methylation |
8 |
|
dna primers |
8 |
|
dose-response relationship, drug |
8 |
|
epigenesis, genetic |
8 |
|
extracellular vesicles |
8 |
|
fatal outcome |
8 |
|
galectin-1 |
8 |
|
glycoproteins - deficiency - genetics - metabolism |
8 |
|
glycoproteins - genetics - metabolism |
8 |
|
hbv integration |
8 |
|
hepatic encephalopathy - surgery |
8 |
|
hepatitis b - complications |
8 |
|
hepatitis b antibodies |
8 |
|
immunotherapy |
8 |
|
inhibitor of differentiation protein 1 |
8 |
|
interleukin-8 - deficiency - genetics - physiology |
8 |
|
length of stay |
8 |
|
liver circulation - physiology |
8 |
|
liver diseases - etiology - surgery |
8 |
|
liver regeneration |
8 |
|
liver transplantation - adverse effects - statistics & numerical data |
8 |
|
liver transplantation - contraindications - methods - mortality - statistics & numerical data |
8 |
|
liver transplantation - immunology |
8 |
|
liver transplantation - mortality |
8 |
|
living donor liver transplant |
8 |
|
living-related liver transplantation |
8 |
|
microcirculation |
8 |
|
mir-22 |
8 |
|
mitochondria |
8 |
|
neoplastic cells, circulating - pathology |
8 |
|
organ size |
8 |
|
otx008 |
8 |
|
pediatric liver transplant |
8 |
|
phosphatidylinositol 3-kinases - metabolism |
8 |
|
phosphorylation |
8 |
|
portoenterostomy, hepatic |
8 |
|
postoperative complications - classification - epidemiology |
8 |
|
postoperative complications - prevention & control |
8 |
|
protein-serine-threonine kinases - metabolism |
8 |
|
rab20 gtpase |
8 |
|
reduced-size liver transplant |
8 |
|
reduced-size liver transplantation |
8 |
|
retinoblastoma protein - genetics - metabolism |
8 |
|
rna, messenger - genetics - metabolism |
8 |
|
rna, messenger - metabolism |
8 |
|
rsk2 |
8 |
|
sensitivity and specificity |
8 |
|
sphingosine - analogs & derivatives |
8 |
|
splicing |
8 |
|
tissue donors - statistics & numerical data |
8 |
|
transcription factors - genetics - metabolism - physiology |
8 |
|
triosephosphate isomerase 1 |
8 |
|
tumor markers, biological - analysis |
8 |
|
tumor suppressor proteins - chemistry - genetics - metabolism |
8 |
|
tumorigenesis |
8 |
|
actins - metabolism |
7 |
|
activities of daily living |
7 |
|
amino acid motifs |
7 |
|
anastomosis, roux-en-y |
7 |
|
anastomosis, surgical - methods |
7 |
|
beta catenin - metabolism |
7 |
|
bile duct diseases - etiology |
7 |
|
bile ducts - blood supply - surgery |
7 |
|
biliary atresia |
7 |
|
biopsy |
7 |
|
cadaveric transplantation |
7 |
|
cadherins - genetics - metabolism |
7 |
|
cancer therapy |
7 |
|
carcinoma, hepatocellular - enzymology - genetics |
7 |
|
carcinoma, hepatocellular - enzymology - pathology |
7 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
7 |
|
carcinoma, hepatocellular - genetics - mortality - secondary |
7 |
|
carcinoma, hepatocellular - pathology |
7 |
|
caveolin 1 - genetics - metabolism |
7 |
|
caveolin-1 |
7 |
|
cell cycle proteins - metabolism |
7 |
|
circular dichroism |
7 |
|
clone cells |
7 |
|
cohort studies |
7 |
|
cyclin-dependent kinase inhibitor p21 |
7 |
|
cyclin-dependent kinase inhibitor p27 |
7 |
|
cytoplasm - metabolism |
7 |
|
diagnosis, differential |
7 |
|
dna mutational analysis |
7 |
|
drug resistance, viral - genetics |
7 |
|
focal adhesion kinase 2 - metabolism |
7 |
|
graft rejection |
7 |
|
hepatectomy - methods |
7 |
|
hepatic artery - surgery |
7 |
|
hepatitis - surgery |
7 |
|
hepatitis b - drug therapy - prevention & control - surgery |
7 |
|
hepatitis b core antigens - genetics |
7 |
|
hepatitis b e antigens - blood |
7 |
|
hepatitis b virus - genetics |
7 |
|
histocompatibility |
7 |
|
icc |
7 |
|
immunoenzyme techniques |
7 |
|
invasiveness |
7 |
|
lipid-binding |
7 |
|
liver |
7 |
|
liver carcinogenesis |
7 |
|
liver diseases - congenital - mortality - surgery |
7 |
|
liver diseases - epidemiology - surgery |
7 |
|
liver failure - surgery |
7 |
|
liver neoplasms - enzymology - genetics |
7 |
|
liver neoplasms - enzymology - pathology |
7 |
|
liver neoplasms - genetics - metabolism - pathology - virology |
7 |
|
liver transplantation - adverse effects - methods - mortality |
7 |
|
liver transplantation - adverse effects - methods - pathology - statistics & numerical data |
7 |
|
liver transplantation - methods - physiology |
7 |
|
living donors - classification |
7 |
|
long-term outcome |
7 |
|
micelles |
7 |
|
microrna |
7 |
|
microsurgery |
7 |
|
microvascular anastomosis |
7 |
|
models, molecular |
7 |
|
mutation - genetics |
7 |
|
mutation screening |
7 |
|
nmr |
7 |
|
nuclear magnetic resonance, biomolecular |
7 |
|
nucleic acid hybridization |
7 |
|
olt |
7 |
|
pediatric liver transplantation |
7 |
|
pfkfb |
7 |
|
phospholipids - chemistry - metabolism |
7 |
|
phosphoproteins - genetics - metabolism |
7 |
|
postoperative care |
7 |
|
postoperative complications - prevention & control - surgery |
7 |
|
preoperative care |
7 |
|
proliferating cell nuclear antigen |
7 |
|
proliferating cell nuclear antigen - analysis |
7 |
|
proline-rich tyrosine kinase2 (pyk2) |
7 |
|
promoter regions, genetic |
7 |
|
promoter regions, genetic - genetics |
7 |
|
proportional hazards models |
7 |
|
propylene glycols - pharmacology |
7 |
|
protein binding |
7 |
|
proto-oncogene proteins - metabolism |
7 |
|
rats |
7 |
|
rats, sprague-dawley |
7 |
|
registries |
7 |
|
risk factors |
7 |
|
sepsis - prevention & control |
7 |
|
sequence alignment |
7 |
|
serum albumin - analysis |
7 |
|
sodium dodecyl sulfate |
7 |
|
solutions - chemistry |
7 |
|
stat5 transcription factor - biosynthesis - genetics - metabolism |
7 |
|
stents |
7 |
|
sterile α-motif (sam) |
7 |
|
structures |
7 |
|
thrombosis - prevention & control |
7 |
|
tumor recurrence |
7 |
|
tumor suppressor protein p53 - metabolism |
7 |
|
tumourigenesis |
7 |
|
vascular surgical procedures - methods |
7 |
|
wnt proteins - metabolism |
7 |
|
acute kidney injury - surgery |
6 |
|
adrenal cortex hormones - administration & dosage |
6 |
|
analysis of variance |
6 |
|
animal model |
6 |
|
antibodies, monoclonal - administration & dosage - therapeutic use |
6 |
|
antigens, cd34 - metabolism |
6 |
|
antigens, differentiation - metabolism |
6 |
|
antigens, viral - blood |
6 |
|
antineoplastic agents - adverse effects - therapeutic use |
6 |
|
asia |
6 |
|
aspartate aminotransferases - blood |
6 |
|
azathioprine - therapeutic use |
6 |
|
cancer stemness |
6 |
|
cancer stemness plasticity |
6 |
|
carcinoma, hepatocellular - blood - metabolism |
6 |
|
carcinoma, hepatocellular - drug therapy - metabolism - secondary |
6 |
|
carcinoma, hepatocellular - drug therapy - pathology - surgery - virology |
6 |
|
carcinoma, hepatocellular - etiology |
6 |
|
carcinoma, hepatocellular - genetics |
6 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology |
6 |
|
carcinoma, hepatocellular - genetics - mortality - pathology - surgery - therapy |
6 |
|
carcinoma, hepatocellular - genetics - pathology |
6 |
|
cardiac myosins - metabolism |
6 |
|
cause of death |
6 |
|
cell cycle - genetics |
6 |
|
cell separation |
6 |
|
chemoembolization, therapeutic |
6 |
|
cyclin d1 - metabolism |
6 |
|
cytomegalovirus - immunology |
6 |
|
data mining |
6 |
|
diabetes mellitus - epidemiology - prevention & control |
6 |
|
dkk1 |
6 |
|
dna - analysis |
6 |
|
dna, viral - blood |
6 |
|
endothelin-1 - genetics - metabolism |
6 |
|
endothelium, vascular - pathology |
6 |
|
enzyme inhibitors - pharmacology |
6 |
|
eph receptor |
6 |
|
ephrin-a |
6 |
|
epigenetics |
6 |
|
feedback signaling |
6 |
|
flow cytometry |
6 |
|
g1 phase - drug effects |
6 |
|
gastrin |
6 |
|
gastroenterology |
6 |
|
gene expression regulation - physiology |
6 |
|
genes, tumor suppressor |
6 |
|
genetic association |
6 |
|
glycogen synthase kinase 3 - metabolism |
6 |
|
glycoproteins - metabolism |
6 |
|
graft rejection - epidemiology - prevention & control |
6 |
|
graft vs host disease - drug therapy - etiology - pathology |
6 |
|
gtpase-activating proteins |
6 |
|
gtpase-activating proteins - genetics - metabolism |
6 |
|
hepatic veins - pathology |
6 |
|
hepatitis b - prevention & control - surgery |
6 |
|
hepatitis b surface antigens - analysis - blood |
6 |
|
hepatitis b surface antigens - blood - immunology |
6 |
|
hepatitis b virus - genetics - immunology |
6 |
|
hepatitis b, chronic - blood - complications - immunology - pathology - virology |
6 |
|
hepatitis b, chronic - mortality - surgery |
6 |
|
heterogeneity |
6 |
|
hypertension, portal - etiology - physiopathology |
6 |
|
immunosuppressive agents - administration & dosage - therapeutic use |
6 |
|
immunosuppressive agents - pharmacology |
6 |
|
in situ hybridization, fluorescence |
6 |
|
informed consent |
6 |
|
injections, intravenous |
6 |
|
intercellular signaling peptides and proteins - blood - metabolism |
6 |
|
interferon-alpha - adverse effects - therapeutic use |
6 |
|
jnk |
6 |
|
ligation |
6 |
|
liver - blood supply - pathology |
6 |
|
liver - metabolism - pathology - physiopathology |
6 |
|
liver - pathology - ultrasonography |
6 |
|
liver cirrhosis - etiology |
6 |
|
liver diseases - surgery |
6 |
|
liver neoplasms - blood - metabolism |
6 |
|
liver neoplasms - blood supply - surgery - ultrastructure |
6 |
|
liver neoplasms - drug therapy - pathology - surgery - virology |
6 |
|
liver neoplasms - etiology |
6 |
|
liver neoplasms - genetics |
6 |
|
liver neoplasms - genetics - metabolism - pathology |
6 |
|
liver neoplasms - genetics - mortality - pathology - surgery - therapy |
6 |
|
liver neoplasms - genetics - pathology |
6 |
|
liver neoplasms, experimental - drug therapy - metabolism - pathology |
6 |
|
liver transplantation - adverse effects |
6 |
|
liver transplantation - adverse effects - immunology |
6 |
|
liver transplantation - adverse effects - pathology - physiology |
6 |
|
liver transplantation - pathology |
6 |
|
map kinase signaling system - drug effects |
6 |
|
mice, knockout |
6 |
|
mice, scid |
6 |
|
microscopy, electron |
6 |
|
microscopy, fluorescence |
6 |
|
mitochondria, liver - pathology |
6 |
|
mitogen-activated protein kinase 1 - antagonists & inhibitors - metabolism |
6 |
|
mitogen-activated protein kinase 3 - antagonists & inhibitors - metabolism |
6 |
|
muscle development |
6 |
|
mycophenolic acid - administration & dosage - analogs & derivatives |
6 |
|
myosin light chains - metabolism |
6 |
|
neoplasm proteins - metabolism |
6 |
|
neovascularization, pathologic - prevention & control |
6 |
|
neuroendocrine carcinoma |
6 |
|
nitric oxide synthase - genetics - metabolism |
6 |
|
nitric oxide synthase type ii |
6 |
|
nitric oxide synthase type iii |
6 |
|
nuclear factor kappa b |
6 |
|
nuclear met |
6 |
|
nuclear proteins - analysis |
6 |
|
omeprazole |
6 |
|
organ size - physiology |
6 |
|
p21/waf1 |
6 |
|
pancreatic tumor |
6 |
|
peptides - metabolism |
6 |
|
phosphatidylinositol 3-kinases - antagonists & inhibitors - metabolism |
6 |
|
phosphorylation - drug effects |
6 |
|
portal pressure - physiology |
6 |
|
progression |
6 |
|
propylene glycols - therapeutic use |
6 |
|
protein stability |
6 |
|
proto-oncogene proteins c-akt |
6 |
|
rac gtp-binding proteins - chemistry - metabolism |
6 |
|
rac gtp-binding proteins - metabolism |
6 |
|
receptors, interleukin-2 - immunology |
6 |
|
recombinant fusion proteins |
6 |
|
regional blood flow - physiology |
6 |
|
reperfusion injury - pathology |
6 |
|
ros |
6 |
|
safety |
6 |
|
sex factors |
6 |
|
single-cell sequencing |
6 |
|
srebp |
6 |
|
stc1 |
6 |
|
stem cells - metabolism - pathology |
6 |
|
tacrolimus - administration & dosage |
6 |
|
tacrolimus - therapeutic use |
6 |
|
tissue and organ procurement - organization & administration |
6 |
|
transforming growth factor beta-activated kinase 1 |
6 |
|
transplantation, heterologous |
6 |
|
tumor markers, biological - blood |
6 |
|
tumor markers, biological - blood - metabolism |
6 |
|
tumor suppressor proteins - genetics - physiology |
6 |
|
tumor suppressor proteins - metabolism |
6 |
|
vascular endothelial growth factor a - metabolism |
6 |
|
von willebrand factor |
6 |
|
wnt |
6 |
|
wound healing |
6 |
|
zollinger-ellison syndrome |
6 |
|
2-de |
5 |
|
3t3 cells |
5 |
|
acute-phase reaction - metabolism - pathology |
5 |
|
adenine - analogs & derivatives - therapeutic use |
5 |
|
adrenal cortex hormones - therapeutic use |
5 |
|
alanine transaminase - analysis |
5 |
|
albumins - genetics - metabolism |
5 |
|
antineoplastic agents - therapeutic use |
5 |
|
antineoplastic agents, hormonal - therapeutic use |
5 |
|
antioxidants |
5 |
|
area under curve |
5 |
|
azacitidine - analogs & derivatives - pharmacology |
5 |
|
biliary tract diseases - chemically induced - diagnosis |
5 |
|
biological markers - blood |
5 |
|
biopsy, needle |
5 |
|
biopsy, needle - adverse effects - methods |
5 |
|
blood loss, surgical - prevention & control |
5 |
|
blood transfusion |
5 |
|
bone marrow transplantation - adverse effects |
5 |
|
cancer biomarker |
5 |
|
cancer cell culture |
5 |
|
carcinogenicity |
5 |
|
carcinoma |
5 |
|
carcinoma - secondary - surgery |
5 |
|
carcinoma, hepatocellular - blood - blood supply - pathology |
5 |
|
carcinoma, hepatocellular - blood - diagnosis - surgery |
5 |
|
carcinoma, hepatocellular - chemistry - drug therapy - mortality |
5 |
|
carcinoma, hepatocellular - complications - diagnosis - surgery |
5 |
|
carcinoma, hepatocellular - complications - pathology - surgery |
5 |
|
carcinoma, hepatocellular - diagnosis - mortality |
5 |
|
carcinoma, hepatocellular - drug therapy - metabolism - pathology |
5 |
|
carcinoma, hepatocellular - enzymology - genetics - pathology |
5 |
|
carcinoma, hepatocellular - genetics - pathology - surgery |
5 |
|
carcinoma, hepatocellular - metabolism - mortality - secondary |
5 |
|
cell adhesion - physiology |
5 |
|
cell assay |
5 |
|
cell cycle |
5 |
|
cell cycle - drug effects |
5 |
|
cell growth |
5 |
|
cell shape |
5 |
|
cell survival |
5 |
|
cell transformation, neoplastic |
5 |
|
cell transformation, neoplastic - genetics - metabolism |
5 |
|
cell-free circulating nucleic acid |
5 |
|
chemoprevention - methods |
5 |
|
china |
5 |
|
china - ethnology |
5 |
|
cholangiocarcinoma - complications - pathology - surgery |
5 |
|
cholangiopancreatography, endoscopic retrograde |
5 |
|
cholestasis, intrahepatic - drug therapy - etiology - surgery |
5 |
|
colorectal neoplasms - pathology |
5 |
|
combined modality therapy |
5 |
|
computer systems |
5 |
|
confidence intervals |
5 |
|
controlled study |
5 |
|
cytokines - blood - genetics |
5 |
|
deleted in liver cancer 1 |
5 |
|
disease transmission, infectious |
5 |
|
dli |
5 |
|
dna - chemistry |
5 |
|
dna, complementary |
5 |
|
dna, complementary - metabolism |
5 |
|
dna, neoplasm - analysis |
5 |
|
dna, neoplasm - metabolism |
5 |
|
donor/recipient origin |
5 |
|
drug delivery systems - methods |
5 |
|
drug resistance, neoplasm |
5 |
|
electrophoresis, gel, two-dimensional |
5 |
|
emergencies |
5 |
|
endothelial growth factors - blood |
5 |
|
endothelin-1 - blood - genetics |
5 |
|
enzyme activation |
5 |
|
evaluation studies as topic |
5 |
|
fibroblasts - cytology - physiology |
5 |
|
fibrosis |
5 |
|
fish |
5 |
|
gene expression regulation, neoplastic - genetics |
5 |
|
genes, reporter |
5 |
|
glutathione |
5 |
|
graft rejection - drug therapy |
5 |
|
growth suppressor protein |
5 |
|
heat-shock protein |
5 |
|
heat-shock proteins - metabolism |
5 |
|
hematologic neoplasms - complications - therapy |
5 |
|
hematopoietic stem cell transplantation - adverse effects - methods |
5 |
|
heme oxygenase (decyclizing) - genetics |
5 |
|
heme oxygenase-1 |
5 |
|
hepatectomy - adverse effects |
5 |
|
hepatectomy - classification - methods |
5 |
|
hepatectomy - methods - mortality |
5 |
|
hepatic veins - physiopathology - surgery |
5 |
|
hepatitic decompensation |
5 |
|
hepatitis b - complications - drug therapy - surgery |
5 |
|
hepatitis b - complications - etiology |
5 |
|
hepatitis b - drug therapy - genetics - physiopathology - virology |
5 |
|
hepatitis b, chronic - blood - pathology - virology |
5 |
|
hepatocellular |
5 |
|
hippo signaling |
5 |
|
hospital mortality |
5 |
|
hsct |
5 |
|
hsp27 heat-shock proteins |
5 |
|
hsp70 heat-shock proteins - metabolism |
5 |
|
hypertension - epidemiology |
5 |
|
hypertension, portal - mortality - physiopathology - surgery |
5 |
|
iatrogenic disease |
5 |
|
immunoglobulins - therapeutic use |
5 |
|
immunophenotyping |
5 |
|
in situ hybridization |
5 |
|
inhalant abuse - complications |
5 |
|
intraoperative complications |
5 |
|
isoforms |
5 |
|
kaplan-meier estimate |
5 |
|
ketamine - administration and dosage - adverse effects |
5 |
|
ketone bodies - blood |
5 |
|
laparoscopy |
5 |
|
leukemia, large granular lymphocytic - complications - drug therapy |
5 |
|
leukemia, myelogenous, chronic, bcr-abl positive - therapy |
5 |
|
lipid droplets |
5 |
|
liver - metabolism - ultrastructure |
5 |
|
liver - physiology |
5 |
|
liver - physiology - surgery |
5 |
|
liver - radiography |
5 |
|
liver cirrhosis - complications |
5 |
|
liver cirrhosis - complications - virology |
5 |
|
liver cirrhosis - drug therapy - etiology - surgery |
5 |
|
liver diseases - drug therapy - etiology |
5 |
|
liver failure - etiology - surgery |
5 |
|
liver gvhd |
5 |
|
liver neoplasms - blood - blood supply - pathology |
5 |
|
liver neoplasms - blood - diagnosis - surgery |
5 |
|
liver neoplasms - blood - secondary - surgery |
5 |
|
liver neoplasms - blood - surgery |
5 |
|
liver neoplasms - chemistry - drug therapy - mortality |
5 |
|
liver neoplasms - complications - diagnosis - surgery |
5 |
|
liver neoplasms - complications - pathology - surgery |
5 |
|
liver neoplasms - complications - surgery |
5 |
|
liver neoplasms - diagnosis - mortality |
5 |
|
liver neoplasms - drug therapy - metabolism - pathology |
5 |
|
liver neoplasms - enzymology - genetics - pathology |
5 |
|
liver neoplasms - genetics - pathology - surgery |
5 |
|
liver neoplasms - metabolism - mortality - pathology |
5 |
|
liver neoplasms - pathology |
5 |
|
liver transplantation - adverse effects - methods |
5 |
|
liver transplantation - adverse effects - mortality |
5 |
|
liver transplantation - immunology - mortality - physiology |
5 |
|
liver transplantation - methods - mortality - statistics & numerical data |
5 |
|
liver transplantation - methods - pathology |
5 |
|
liver transplantation - mortality - physiology - statistics & numerical data |
5 |
|
living related donor |
5 |
|
logistic models |
5 |
|
loh |
5 |
|
longitudinal studies |
5 |
|
lymphatic metastasis |
5 |
|
lymphocyte transfusion - adverse effects |
5 |
|
lymphokines - blood |
5 |
|
lymphoma, b-cell - etiology - genetics - pathology |
5 |
|
macrophage polarization |
5 |
|
marrow transplantation |
5 |
|
medical errors - adverse effects |
5 |
|
metabolism |
5 |
|
micrornas - metabolism |
5 |
|
microsatellite analysis |
5 |
|
mitochondria, liver - genetics - metabolism |
5 |
|
molecular chaperones - metabolism |
5 |
|
molecular mechanisms |
5 |
|
molecular oncology |
5 |
|
molecular pathogenesis |
5 |
|
mortality |
5 |
|
mutations |
5 |
|
n-acetylcysteine |
5 |
|
neoplasm recurrence, local - blood - diagnosis |
5 |
|
neoplasm recurrence, local - mortality |
5 |
|
neoplasm seeding |
5 |
|
neoplastic stem cells - drug effects |
5 |
|
non-coding rna |
5 |
|
nrf2 |
5 |
|
opportunistic infections |
5 |
|
organ transplantation - adverse effects - pathology |
5 |
|
orthotopic liver transplantation |
5 |
|
overexpression |
5 |
|
palliative care - methods |
5 |
|
pathology |
5 |
|
patient selection |
5 |
|
phosphonic acids |
5 |
|
plasma mrna |
5 |
|
point mutation |
5 |
|
portal vein - physiopathology - surgery |
5 |
|
post-transplantation lymphoproliferative disorder |
5 |
|
postoperative complications - etiology |
5 |
|
postoperative complications - etiology - pathology |
5 |
|
preoperative care - methods |
5 |
|
probability |
5 |
|
prognostic marker |
5 |
|
prostatic neoplasms - drug therapy - pathology - prevention and control |
5 |
|
protein isoforms - genetics - metabolism |
5 |
|
protein structure, tertiary - genetics |
5 |
|
protein transport - genetics |
5 |
|
protein-losing enteropathies - drug therapy - etiology |
5 |
|
proteoglycans - pharmacology - therapeutic use |
5 |
|
proteome - metabolism |
5 |
|
reactive oxygen species |
5 |
|
receptors, endothelin - genetics |
5 |
|
receptors, estrogen - analysis |
5 |
|
receptors, progesterone - analysis |
5 |
|
recombinant fusion proteins - genetics - metabolism |
5 |
|
reference values |
5 |
|
referral and consultation |
5 |
|
rho-associated kinases - analysis - metabolism |
5 |
|
rhoa gtp-binding protein - antagonists & inhibitors - metabolism |
5 |
|
risk assessment |
5 |
|
rna - metabolism |
5 |
|
rna, messenger - blood |
5 |
|
rupture - etiology - mortality - pathology |
5 |
|
severe hepatitis b exacerbation |
5 |
|
signaling pathways |
5 |
|
single-blind method |
5 |
|
single-cell rna sequencing |
5 |
|
spectrometry, mass, matrix-assisted laser desorption-ionization |
5 |
|
steroidogenic acute regulatory protein-related lipid transfer domain |
5 |
|
steroids - therapeutic use |
5 |
|
tamoxifen - therapeutic use |
5 |
|
tissue distribution |
5 |
|
tissue donors - supply & distribution |
5 |
|
tmbim1 |
5 |
|
tomography, x-ray computed |
5 |
|
trans-activators - metabolism |
5 |
|
transcription factors - analysis |
5 |
|
transcription, genetic |
5 |
|
transferrin - analysis |
5 |
|
tumor progression |
5 |
|
tumor stem cell assay |
5 |
|
tumorigenicity |
5 |
|
ultrastructure |
5 |
|
urologic diseases - chemically induced |
5 |
|
vascular endothelial growth factor a |
5 |
|
vascular endothelial growth factors |
5 |
|
venous infiltration |
5 |
|
virus integration |
5 |
|
yes-associated protein |
5 |
|
ymdd mutation |
5 |
|
actuarial analysis |
4 |
|
adaptor proteins, signal transducing - genetics - metabolism |
4 |
|
adaptor proteins, signal transducing - metabolism |
4 |
|
adenine - analogs and derivatives - therapeutic use |
4 |
|
adenocarcinoma - metabolism - pathology |
4 |
|
afp |
4 |
|
aldose reductase |
4 |
|
alkaline phosphatase - blood |
4 |
|
alleles |
4 |
|
alpha catenin |
4 |
|
animal |
4 |
|
antibiotics, antineoplastic - pharmacology |
4 |
|
antibodies, monoclonal - diagnostic use |
4 |
|
antigens, cd34 - analysis |
4 |
|
apobec3 |
4 |
|
bagg albino mouse |
4 |
|
basic fibroblast growth factor |
4 |
|
biomarkers |
4 |
|
blood loss, surgical - statistics & numerical data |
4 |
|
blood transfusion - adverse effects |
4 |
|
bone marrow cells - pathology |
4 |
|
breast neoplasms - pathology |
4 |
|
bzip transcription factors |
4 |
|
c57bl mouse |
4 |
|
cadherin-17 |
4 |
|
cadherins - metabolism |
4 |
|
cancer screening |
4 |
|
cancer vaccines |
4 |
|
cancer-associated fibroblasts (cafs) |
4 |
|
capping actin protein gelsolin-like |
4 |
|
carboxypeptidase h - chemistry - genetics |
4 |
|
carcinoma, hepatocellular - blood - diagnosis - pathology |
4 |
|
carcinoma, hepatocellular - blood - mortality - pathology - surgery |
4 |
|
carcinoma, hepatocellular - blood supply - immunology |
4 |
|
carcinoma, hepatocellular - chemically induced - metabolism |
4 |
|
carcinoma, hepatocellular - classification - pathology - surgery |
4 |
|
carcinoma, hepatocellular - complications - surgery |
4 |
|
carcinoma, hepatocellular - diagnosis - surgery |
4 |
|
carcinoma, hepatocellular - drug therapy - pathology - surgery |
4 |
|
carcinoma, hepatocellular - ethnology - genetics - pathology |
4 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - secondary |
4 |
|
carcinoma, hepatocellular - genetics - pathology - virology |
4 |
|
carcinoma, hepatocellular - immunology - pathology - therapy |
4 |
|
carcinoma, hepatocellular - metabolism - pathology - physiopathology |
4 |
|
carcinoma, hepatocellular - pathology - surgery - virology |
4 |
|
carcinoma, hepatocellular - therapy |
4 |
|
catenin |
4 |
|
cdc42 gtp-binding protein - metabolism |
4 |
|
cell division - drug effects |
4 |
|
cell growth suppression |
4 |
|
cell hypoxia |
4 |
|
cell membrane - drug effects - metabolism |
4 |
|
cell movement - physiology |
4 |
|
cell nucleus - metabolism |
4 |
|
cells, cultured |
4 |
|
cgh |
4 |
|
chemical carcinogenesis |
4 |
|
chemoresistance |
4 |
|
chemotherapy, adjuvant |
4 |
|
cholangiocarcinoma - pathology - surgery |
4 |
|
cholestasis |
4 |
|
cholestasis - etiology |
4 |
|
chromatin assembly and disassembly |
4 |
|
chromosomes, human, pair 13 |
4 |
|
chromosomes, human, y |
4 |
|
cirrhosis |
4 |
|
clathrin light chain a |
4 |
|
clustered regularly interspaced short palindromic repeat |
4 |
|
codon |
4 |
|
collagen - metabolism |
4 |
|
combined hcc-cc |
4 |
|
complications of hbv reactivation |
4 |
|
consensus sequence |
4 |
|
core-promoter mutation |
4 |
|
cpg islands - genetics |
4 |
|
creb-h |
4 |
|
crispr library screening |
4 |
|
cyclic amp response element-binding protein - chemistry - genetics - metabolism |
4 |
|
cytoskeletal proteins - metabolism |
4 |
|
dendritic cells - immunology |
4 |
|
dendritic cells - pathology |
4 |
|
deoxyribonucleases, type ii site-specific |
4 |
|
diethylnitrosamine |
4 |
|
discriminant analysis |
4 |
|
dlc2 (deleted in liver cancer 2) |
4 |
|
dna deaminase |
4 |
|
dna, neoplasm - genetics |
4 |
|
dna, viral - genetics |
4 |
|
drug reaction |
4 |
|
drug-resistance |
4 |
|
e-cadherin |
4 |
|
endocytosis |
4 |
|
endoplasmic reticulum |
4 |
|
er stress |
4 |
|
extracellular matrix |
4 |
|
extrahepatic manifestation of hbv |
4 |
|
fibroblast growth factor 2 - blood |
4 |
|
fluorescent antibody technique |
4 |
|
follicular dendritic cell |
4 |
|
fra1 |
4 |
|
gastric cancer |
4 |
|
gata |
4 |
|
genes, tumor suppressor - physiology |
4 |
|
genetic alterations |
4 |
|
genetic transfection |
4 |
|
genotype |
4 |
|
glycoproteins - genetics |
4 |
|
golgi apparatus - physiology |
4 |
|
graft rejection - drug therapy - pathology |
4 |
|
graft vs host disease - diagnosis - etiology - pathology |
4 |
|
graft vs host disease - epidemiology |
4 |
|
gtpase-activating proteins - chemistry - genetics - physiology |
4 |
|
gtpase-activating proteins - genetics |
4 |
|
hematopoietic stem cell transplantation - adverse effects |
4 |
|
hemostasis, surgical |
4 |
|
hepatectomy - adverse effects - contraindications - methods - mortality |
4 |
|
hepatic bipotent cells |
4 |
|
hepatitis - drug therapy - etiology - pathology |
4 |
|
hepatitis b - complications - pathology - surgery |
4 |
|
hepatitis b - drug therapy - etiology - pathology |
4 |
|
hepatitis b - epidemiology |
4 |
|
hepatitis b core antigens - metabolism |
4 |
|
hepatitis b e antigens - metabolism |
4 |
|
hepatitis b genotype |
4 |
|
hepatitis b surface antigens - blood |
4 |
|
hepatitis b virus - isolation & purification |
4 |
|
hepatitis b, chronic - genetics - metabolism - pathology |
4 |
|
hepatitis b, chronic - pathology - physiopathology |
4 |
|
hepatitis, chronic - complications - surgery |
4 |
|
hepatocarcinogenesis |
4 |
|
hepatocyte growth factor (hgf) |
4 |
|
hepatocytes - cytology |
4 |
|
hepatocytes - metabolism |
4 |
|
hey1 |
4 |
|
high mortality of acute pancreatitis |
4 |
|
histocompatibility testing |
4 |
|
histology |
4 |
|
hla |
4 |
|
hla antigens - analysis |
4 |
|
hsp70 heat-shock proteins - genetics - metabolism |
4 |
|
hypertension, portal - complications - surgery |
4 |
|
hypoxia-inducible factor 1 - genetics - physiology |
4 |
|
i-kappa b kinase - genetics - metabolism |
4 |
|
ikk |
4 |
|
image interpretation, computer-assisted |
4 |
|
immune regulation |
4 |
|
immunologic memory - immunology |
4 |
|
immunosuppression - methods |
4 |
|
indocyanine green - diagnostic use |
4 |
|
inhibitor |
4 |
|
interferon-alpha - therapeutic use |
4 |
|
interleukin-10 - deficiency - genetics - immunology - metabolism |
4 |
|
interleukin-6 - genetics - metabolism |
4 |
|
intestinal metaplasia |
4 |
|
intrahepatic metastasis |
4 |
|
iron - analysis |
4 |
|
iκb |
4 |
|
kidney - cytology |
4 |
|
kupffer cells - cytology |
4 |
|
large |
4 |
|
leukemia - therapy |
4 |
|
lim domain proteins |
4 |
|
liquid biopsy |
4 |
|
liver cirrhosis - complications - surgery |
4 |
|
liver cirrhosis - diagnosis - surgery |
4 |
|
liver cirrhosis - pathology - physiopathology |
4 |
|
liver diseases - drug therapy - etiology - pathology |
4 |
|
liver diseases - etiology - pathology |
4 |
|
liver neoplasms - blood - diagnosis - pathology |
4 |
|
liver neoplasms - blood - mortality - pathology - surgery |
4 |
|
liver neoplasms - blood supply - immunology |
4 |
|
liver neoplasms - classification - mortality - pathology - surgery |
4 |
|
liver neoplasms - diagnosis - surgery |
4 |
|
liver neoplasms - drug therapy - pathology - surgery |
4 |
|
liver neoplasms - ethnology - genetics - pathology |
4 |
|
liver neoplasms - genetics - metabolism - pathology - secondary |
4 |
|
liver neoplasms - genetics - pathology - secondary - virology |
4 |
|
liver neoplasms - metabolism - pathology - physiopathology |
4 |
|
liver neoplasms - metabolism - pathology - surgery |
4 |
|
liver neoplasms - pathology - surgery - virology |
4 |
|
liver neoplasms - therapy |
4 |
|
liver neoplasms, experimental - chemically induced - metabolism |
4 |
|
liver transplantation - immunology - methods |
4 |
|
liver transplantation - immunology - pathology |
4 |
|
liver-enriched transcription factors |
4 |
|
luciferases - metabolism |
4 |
|
lung metastasis |
4 |
|
lymphocytes - pathology |
4 |
|
lymphoma - therapy |
4 |
|
macrophages - cytology |
4 |
|
magnetic resonance imaging |
4 |
|
membrane proteins - genetics - metabolism |
4 |
|
membrane-bound transcription factors |
4 |
|
micro-rna |
4 |
|
mir-874-3p |
4 |
|
mixed tumor, malignant - pathology - surgery |
4 |
|
molecular relationship |
4 |
|
mouse model |
4 |
|
multicentric occurrence |
4 |
|
multinodular |
4 |
|
multiple myeloma - therapy |
4 |
|
myosin-light-chain phosphatase - metabolism |
4 |
|
n-linked glycosylation |
4 |
|
necroinflammation |
4 |
|
neoplasm recurrence, local - blood supply |
4 |
|
neoplasm recurrence, local - pathology - surgery |
4 |
|
neoplastic stem cells - pathology |
4 |
|
nf-kappa b - analysis - metabolism |
4 |
|
nf-kappa b - biosynthesis |
4 |
|
nf-κb |
4 |
|
notch signaling |
4 |
|
nucleic acid hybridization - methods |
4 |
|
oncogene |
4 |
|
pancreatitis - diagnosis - etiology |
4 |
|
patient-derived xenografts |
4 |
|
phosphonic acids - therapeutic use |
4 |
|
pim kinase |
4 |
|
pitstop 2 |
4 |
|
plasmids - metabolism |
4 |
|
plasticity |
4 |
|
post-translational modification |
4 |
|
precancerous conditions - metabolism - pathology |
4 |
|
precore mutation |
4 |
|
prevalence |
4 |
|
primary liver tumours |
4 |
|
pringle manoeuvre |
4 |
|
protein processing, post-translational - drug effects |
4 |
|
protein-losing enteropathies - etiology - surgery |
4 |
|
proteomics - methods |
4 |
|
pseudopodia - metabolism |
4 |
|
rac1 gtp-binding protein - metabolism |
4 |
|
raf-1-erk1/2-p70s6k signalling |
4 |
|
ras proteins - metabolism |
4 |
|
regulated intramembrane proteolysis |
4 |
|
reprogramming |
4 |
|
rho gtpase |
4 |
|
rho-associated kinase |
4 |
|
rho-associated kinases - metabolism |
4 |
|
rhoa gtp-binding protein - metabolism |
4 |
|
rna, messenger - biosynthesis - genetics |
4 |
|
scd1 |
4 |
|
sepsis |
4 |
|
sequence analysis, dna |
4 |
|
severity of illness index |
4 |
|
skin - pathology |
4 |
|
small-for-size fatty graft injury |
4 |
|
sphere formation |
4 |
|
stem cell transplantation - adverse effects |
4 |
|
stemness |
4 |
|
stomach neoplasms - metabolism - pathology |
4 |
|
stress |
4 |
|
stress fibers - metabolism |
4 |
|
survival |
4 |
|
t-ics |
4 |
|
tace |
4 |
|
therapeutic target |
4 |
|
trans-activators - biosynthesis |
4 |
|
transcription factors - analysis - classification - metabolism - physiology |
4 |
|
transcription, genetic - drug effects |
4 |
|
transcriptional activation - drug effects |
4 |
|
transplantation chimera |
4 |
|
tumor detection |
4 |
|
tumor necrosis factor-alpha - genetics - metabolism |
4 |
|
tumor size |
4 |
|
tumor suppressor protein p53 - biosynthesis - genetics |
4 |
|
tumor suppressor proteins - metabolism - physiology |
4 |
|
tumor-initiating cells (t-ics) |
4 |
|
ubiquitin - metabolism |
4 |
|
unfolded protein response |
4 |
|
urokinase-type plasminogen activator - biosynthesis |
4 |
|
vimentin - blood |
4 |
|
wnt signaling |
4 |
|
wnt/β-catenin |
4 |
|
y chromosome - genetics |
4 |
|
acetylation |
3 |
|
adaptor proteins, signal transducing |
3 |
|
adenocarcinoma - pathology |
3 |
|
adenoma - blood - complications - pathology |
3 |
|
adipose tissue - physiology |
3 |
|
adrenocorticotropic hormone - blood |
3 |
|
akt |
3 |
|
allograft |
3 |
|
alpha-fetoproteins - metabolism |
3 |
|
alternative splicing |
3 |
|
angiogenesis |
3 |
|
antigens, cd |
3 |
|
antigens, cd - analysis |
3 |
|
antigens, cd79 |
3 |
|
antineoplastic agents - administration & dosage |
3 |
|
beta-galactosidase - metabolism |
3 |
|
beta-thalassemia - drug therapy - metabolism - therapy |
3 |
|
bile duct neoplasms - complications - mortality - therapy |
3 |
|
bile ducts, intrahepatic - pathology - radiography - ultrasonography |
3 |
|
binding sites |
3 |
|
blood loss, surgical - physiopathology |
3 |
|
blood transfusion, autologous |
3 |
|
blotting, northern |
3 |
|
bone marrow cells |
3 |
|
brefeldin a - pharmacology |
3 |
|
cadherins |
3 |
|
calcium-binding proteins - metabolism - physiology |
3 |
|
calcium-binding proteins - physiology |
3 |
|
cancer genetics |
3 |
|
cancer inhibition |
3 |
|
cancer metabolism |
3 |
|
cancer stem cells |
3 |
|
candidiasis - chemically induced - pathology |
3 |
|
carcinoma, hepatocellular - blood - complications - pathology |
3 |
|
carcinoma, hepatocellular - blood - mortality |
3 |
|
carcinoma, hepatocellular - blood supply - pathology - surgery |
3 |
|
carcinoma, hepatocellular - complications - ethnology - genetics |
3 |
|
carcinoma, hepatocellular - diagnosis |
3 |
|
carcinoma, hepatocellular - drug therapy |
3 |
|
carcinoma, hepatocellular - drug therapy - genetics - mortality |
3 |
|
carcinoma, hepatocellular - enzymology - genetics - metabolism - pathology |
3 |
|
carcinoma, hepatocellular - epidemiology - genetics - pathology |
3 |
|
carcinoma, hepatocellular - genetics - metabolism - mortality |
3 |
|
carcinoma, hepatocellular - genetics - metabolism - mortality - pathology |
3 |
|
carcinoma, hepatocellular - genetics - metabolism - physiopathology |
3 |
|
carcinoma, hepatocellular - genetics - mortality - pathology - secondary |
3 |
|
carcinoma, hepatocellular - genetics - physiopathology |
3 |
|
carcinoma, hepatocellular - metabolism - therapy |
3 |
|
carcinoma, hepatocellular - mortality - pathology - virology |
3 |
|
carcinoma, hepatocellular - pathology - physiopathology - surgery |
3 |
|
carcinoma, squamous cell - genetics - pathology - radiotherapy |
3 |
|
carrier proteins - biosynthesis |
3 |
|
caveolae - pathology - physiology |
3 |
|
cd24 antigen |
3 |
|
cd47 |
3 |
|
cdk1 |
3 |
|
cell component |
3 |
|
cell cycle control |
3 |
|
cell cycle proteins |
3 |
|
cell cycle proteins - analysis - genetics - physiology |
3 |
|
cell nucleus - chemistry |
3 |
|
cell nucleus - drug effects - metabolism |
3 |
|
cell renewal |
3 |
|
cell-free dna |
3 |
|
cellular retinol binding protein |
3 |
|
cfi-402257 |
3 |
|
chi-square distribution |
3 |
|
chinese |
3 |
|
chinese people |
3 |
|
cholangiocarcinoma |
3 |
|
cholangiocarcinoma - complications - mortality - therapy |
3 |
|
cholangiocarcinoma - mortality - surgery |
3 |
|
chromosomal instability |
3 |
|
chromosome deletion |
3 |
|
chromosomes, human, pair 13 - genetics |
3 |
|
chromosomes, human, pair 8 |
3 |
|
circulating tumor dna |
3 |
|
cisplatin |
3 |
|
clinical |
3 |
|
clinicopathologic correlation |
3 |
|
clinicopathologic correlation and prognostication |
3 |
|
colony-forming units assay |
3 |
|
cscs |
3 |
|
cyclin d1 |
3 |
|
cyclin d1 - genetics |
3 |
|
cytochrome p-450 cyp2e1 - biosynthesis - pharmacology |
3 |
|
cytochrome p450 |
3 |
|
cytokeratin 19 |
3 |
|
cytoplasm - chemistry |
3 |
|
cytoskeletal proteins - antagonists & inhibitors |
3 |
|
cytoskeletal proteins - biosynthesis - genetics |
3 |
|
cytoskeletal reorganization |
3 |
|
cytosolic dna sensing |
3 |
|
dapper |
3 |
|
deferoxamine - therapeutic use |
3 |
|
demethylation |
3 |
|
differential expression |
3 |
|
disease marker |
3 |
|
doxorubicin - pharmacology |
3 |
|
drug design |
3 |
|
drug resistance, multiple |
3 |
|
drug-induced liver injury |
3 |
|
endothelial growth factors - biosynthesis - genetics |
3 |
|
endothelial growth factors - genetics - metabolism |
3 |
|
enoxaparin - adverse effects |
3 |
|
epstein-barr virus |
3 |
|
erk |
3 |
|
exanthema - chemically induced - microbiology |
3 |
|
extracellular matrix proteins - genetics - metabolism |
3 |
|
extramedullary plasmacytoma |
3 |
|
eye neoplasms - diagnosis - pathology - therapy |
3 |
|
fact complex |
3 |
|
fatty acids, unsaturated - pharmacology |
3 |
|
ferritins - blood |
3 |
|
flk-1/kdr |
3 |
|
flt-1 |
3 |
|
g9a |
3 |
|
gastric adenocarcinoma |
3 |
|
gastrointestinal cancer |
3 |
|
gene amplification |
3 |
|
gene therapy - methods |
3 |
|
genes, p16 |
3 |
|
genetic markers - genetics |
3 |
|
genome |
3 |
|
genome instability |
3 |
|
gingival neoplasms - genetics - pathology |
3 |
|
glutathione transferase - metabolism |
3 |
|
glycoproteins |
3 |
|
gtpase-activating proteins - metabolism |
3 |
|
hai-2 |
3 |
|
hbv-associated multistep |
3 |
|
hdpr1 |
3 |
|
hela cells |
3 |
|
hemagglutinins - metabolism |
3 |
|
hemangioma - mortality - surgery |
3 |
|
hepatic resection |
3 |
|
hepatitis b - pathology |
3 |
|
hepatitis b antigens - metabolism |
3 |
|
hepatocytes |
3 |
|
hepatocytes - drug effects - metabolism - pathology |
3 |
|
hirsutism - blood - etiology |
3 |
|
histologic activity index |
3 |
|
histone h3 |
3 |
|
histone modifications |
3 |
|
hottip |
3 |
|
hydrocortisone - blood |
3 |
|
hyperalgesia |
3 |
|
immunogenic cell death |
3 |
|
immunosuppression - adverse effects |
3 |
|
incidental findings |
3 |
|
inflammation |
3 |
|
inflammatory pseudotumour |
3 |
|
intercellular signaling peptides and proteins - biosynthesis |
3 |
|
intercellular signaling peptides and proteins - biosynthesis - genetics |
3 |
|
intercellular signaling peptides and proteins - physiology |
3 |
|
interleukin-8 - biosynthesis - genetics |
3 |
|
intracellular signaling peptides and proteins - metabolism |
3 |
|
intraoperative complications - etiology |
3 |
|
iron chelating agents - therapeutic use |
3 |
|
iron overload |
3 |
|
iron overload - diagnosis - etiology |
3 |
|
jnk mitogen-activated protein kinases - metabolism |
3 |
|
jnk signaling |
3 |
|
keywords: liver cell adenoma, bile pigment, hirsutism, child |
3 |
|
kidney |
3 |
|
knowledge-based genetic association |
3 |
|
kunitz domain |
3 |
|
lacrimal apparatus diseases - diagnosis - pathology - therapy |
3 |
|
lacrimal gland |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - pathology |
3 |
|
leukemia, myeloid - complications - drug therapy |
3 |
|
li-cadherin |
3 |
|
lipid peroxidation |
3 |
|
liver - chemistry - physiopathology |
3 |
|
liver - drug effects - metabolism - pathology |
3 |
|
liver - drug effects - pathology - physiopathology |
3 |
|
liver cirrhosis |
3 |
|
liver cirrhosis - complications - mortality - therapy |
3 |
|
liver cirrhosis - pathology |
3 |
|
liver diseases - genetics - pathology |
3 |
|
liver diseases - mortality - surgery |
3 |
|
liver diseases - pathology - physiopathology - surgery |
3 |
|
liver failure - etiology |
3 |
|
liver iron concentration |
3 |
|
liver neoplasm |
3 |
|
liver neoplasms |
3 |
|
liver neoplasms - blood - complications - pathology |
3 |
|
liver neoplasms - blood - mortality |
3 |
|
liver neoplasms - blood supply - pathology - surgery |
3 |
|
liver neoplasms - complications - ethnology - genetics |
3 |
|
liver neoplasms - drug therapy |
3 |
|
liver neoplasms - drug therapy - genetics - mortality |
3 |
|
liver neoplasms - enzymology - genetics - metabolism - pathology |
3 |
|
liver neoplasms - epidemiology - genetics - pathology |
3 |
|
liver neoplasms - genetics - metabolism - mortality |
3 |
|
liver neoplasms - genetics - metabolism - mortality - pathology |
3 |
|
liver neoplasms - genetics - metabolism - physiopathology |
3 |
|
liver neoplasms - genetics - physiopathology |
3 |
|
liver neoplasms - metabolism - pathology - virology |
3 |
|
liver neoplasms - metabolism - therapy |
3 |
|
liver neoplasms - mortality - pathology - virology |
3 |
|
liver neoplasms - pathology - radiography - surgery |
3 |
|
liver neoplasms, experimental - chemically induced - physiopathology |
3 |
|
liver transplant |
3 |
|
liver tumors |
3 |
|
lncrna |
3 |
|
lymphangioma |
3 |
|
lymphangioma - epidemiology - pathology - surgery |
3 |
|
lymphokines - biosynthesis - genetics |
3 |
|
lymphokines - genetics - metabolism |
3 |
|
lymphoma, follicular - pathology - radiography - surgery |
3 |
|
macrophage migration inhibitory factor |
3 |
|
macrophage migration-inhibitory factors - pharmacology - physiology |
3 |
|
mad2 |
3 |
|
median survival |
3 |
|
membrane glycoproteins - genetics - metabolism |
3 |
|
membrane transport proteins |
3 |
|
microfilament proteins - genetics - metabolism |
3 |
|
microrna expression |
3 |
|
micrornas - genetics - metabolism |
3 |
|
microtubule toxin |
3 |
|
microtubules - metabolism |
3 |
|
microvessel density |
3 |
|
mir-1 |
3 |
|
mir-125b |
3 |
|
mir-200 family |
3 |
|
mirna |
3 |
|
mitosis |
3 |
|
mitotic checkpoint |
3 |
|
mitotic spindle apparatus |
3 |
|
molecular alterations |
3 |
|
mouth floor - pathology |
3 |
|
mouth neoplasms - genetics - pathology - radiotherapy |
3 |
|
multidrug resistance |
3 |
|
multifocal hcc |
3 |
|
muscular diseases - chemically induced - microbiology |
3 |
|
mutagenesis, site-directed |
3 |
|
myocardium - chemistry |
3 |
|
nadroparin - adverse effects |
3 |
|
neoplasm recurrence, local |
3 |
|
neoplasm recurrence, local - surgery |
3 |
|
neoplastic stem cells - drug effects - metabolism - pathology |
3 |
|
neovascularization, pathologic - metabolism |
3 |
|
nerve conduction velocity |
3 |
|
npm |
3 |
|
nuclear accumulation |
3 |
|
nuclear proteins - analysis - genetics - physiology |
3 |
|
nuclear proteins - genetics - physiology |
3 |
|
oligopeptides - metabolism |
3 |
|
oral |
3 |
|
oropharyngeal neoplasms - genetics - pathology |
3 |
|
osteolysis - pathology |
3 |
|
oval cells |
3 |
|
p-glycoprotein |
3 |
|
p-glycoproteins - genetics |
3 |
|
p21-activated kinases |
3 |
|
p53 gene |
3 |
|
p53: hepatocellular carcinoma |
3 |
|
pain |
3 |
|
palatal neoplasms - genetics - pathology |
3 |
|
pancreas |
3 |
|
pancreas - chemistry |
3 |
|
pancreas - pathology |
3 |
|
pancreatic neoplasms - epidemiology - pathology - surgery |
3 |
|
paraneoplastic syndromes - diagnosis - etiology |
3 |
|
paxillin - metabolism |
3 |
|
pentacyclic triterpenes - therapeutic use |
3 |
|
peptides |
3 |
|
phosphoprotein phosphatases - metabolism |
3 |
|
phosphoric monoester hydrolases - genetics - metabolism |
3 |
|
pim1 |
3 |
|
plasmacytoma - diagnosis - pathology - therapy |
3 |
|
polymorphism, single nucleotide |
3 |
|
portal vein thrombosis |
3 |
|
ppp |
3 |
|
prognostic factors |
3 |
|
protein-serine-threonine kinases - biosynthesis - genetics - metabolism |
3 |
|
protein-tyrosine kinases - antagonists & inhibitors |
3 |
|
prothrombin time |
3 |
|
proto-oncogene proteins c-akt - metabolism |
3 |
|
pten phosphohydrolase - physiology |
3 |
|
ptnm classification |
3 |
|
pulmonary embolism - drug therapy |
3 |
|
rarres3 |
3 |
|
receptor protein-tyrosine kinases - genetics - metabolism |
3 |
|
receptor, epidermal growth factor - genetics - metabolism |
3 |
|
receptor-mediated gene transfer system |
3 |
|
receptors, antigen, b-cell - analysis |
3 |
|
receptors, growth factor - genetics - metabolism |
3 |
|
receptors, vascular endothelial growth factor |
3 |
|
regulated cell death |
3 |
|
remission induction |
3 |
|
repressor proteins - physiology |
3 |
|
retinol-binding proteins - metabolism |
3 |
|
retinol-binding proteins, cellular - metabolism |
3 |
|
retroviridae - genetics |
3 |
|
rho |
3 |
|
rho gtp-binding proteins - metabolism |
3 |
|
rho/rock signaling pathway |
3 |
|
rhoa |
3 |
|
rna, neoplasm - genetics |
3 |
|
rna, neoplasm - genetics - isolation & purification |
3 |
|
rna, neoplasm - metabolism |
3 |
|
rock |
3 |
|
rtk |
3 |
|
senescence |
3 |
|
sequence deletion |
3 |
|
serine protease inhibitor |
3 |
|
shp2 |
3 |
|
signal intensity threshold |
3 |
|
signal transduction - genetics - physiology |
3 |
|
sox9 |
3 |
|
spindle assembly checkpoint |
3 |
|
spleen - chemistry |
3 |
|
squamous cell carcinoma |
3 |
|
ssrp1 |
3 |
|
stat3 protein |
3 |
|
statistics, nonparametric |
3 |
|
stem cells - drug effects - metabolism - pathology |
3 |
|
sting pathway |
3 |
|
stomach neoplasms - pathology |
3 |
|
supt16h |
3 |
|
survival outcomes |
3 |
|
susceptibility |
3 |
|
tkt |
3 |
|
tor serine-threonine kinases |
3 |
|
trans-activators |
3 |
|
trans-activators - antagonists & inhibitors |
3 |
|
treatment |
3 |
|
ttk inhibitor |
3 |
|
tumor cells, cultured - metabolism - pathology |
3 |
|
tumor markers, biological |
3 |
|
tumor markers, biological - biosynthesis - genetics |
3 |
|
tumor markers, biological - genetics - metabolism |
3 |
|
tumor suppressor protein p53 - analysis - genetics |
3 |
|
tumor suppressor protein p53 - genetics |
3 |
|
tumor-initiating cells |
3 |
|
ultrasonography, doppler |
3 |
|
vascular endothelial growth factor |
3 |
|
vascular endothelial growth factor a - blood |
3 |
|
vascular endothelial growth factor receptor-1 |
3 |
|
vascular neoplasms - genetics - mortality - secondary |
3 |
|
vegf |
3 |
|
wnt proteins |
3 |
|
wnt/β-catenin signaling |
3 |
|
young. |
3 |
|
acetic acid - therapeutic use |
2 |
|
acetylation - drug effects |
2 |
|
acquired immunodeficiency syndrome |
2 |
|
acute cellular rejection |
2 |
|
adult and foetal transcripts |
2 |
|
age |
2 |
|
alpha fetoprotein blood level |
2 |
|
alpha-fetoproteins - analysis |
2 |
|
ameloblastoma - pathology - surgery |
2 |
|
ampk |
2 |
|
ampulla of vater |
2 |
|
angiography |
2 |
|
angiomyolipoma - pathology - radiography |
2 |
|
antibodies, monoclonal |
2 |
|
anticarcinogenic agents - metabolism |
2 |
|
antigens, neoplasm - analysis - genetics |
2 |
|
antimetabolites, antineoplastic - pharmacology |
2 |
|
antineoplastic agents - pharmacology |
2 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
2 |
|
antithyroid agents |
2 |
|
antithyroid agents - administration & dosage - adverse effects |
2 |
|
apoptosis - drug effects - genetics |
2 |
|
apoptosis - genetics |
2 |
|
arthralgia - chemically induced |
2 |
|
auxiliary liver transplantation |
2 |
|
beta-thalassemia - drug therapy |
2 |
|
bile duct carcinoma |
2 |
|
bile duct diseases - complications |
2 |
|
bile duct neoplasms - mortality - pathology - ultrastructure |
2 |
|
bile ducts, intrahepatic - pathology |
2 |
|
blotting, southern |
2 |
|
blotting, western - methods |
2 |
|
bone marrow transplantation |
2 |
|
brain - pathology |
2 |
|
brain diseases - etiology - physiopathology |
2 |
|
breakpoint detection |
2 |
|
c-jun |
2 |
|
c-myc amplification |
2 |
|
cadherins - drug effects - genetics - metabolism |
2 |
|
campylobacter - isolation & purification |
2 |
|
campylobacter infections - complications - microbiology - pathology |
2 |
|
cancer - prognosis. |
2 |
|
cancer epigenetics |
2 |
|
cancer growth |
2 |
|
cancer immunotherapy |
2 |
|
cancer tissue |
2 |
|
capsular thickness |
2 |
|
carbimazole |
2 |
|
carbimazole - administration & dosage - adverse effects |
2 |
|
carcinogenesis. |
2 |
|
carcinoma showing thymus-like element |
2 |
|
carcinoma, hepatocellular - drug therapy - genetics - metabolism |
2 |
|
carcinoma, hepatocellular - drug therapy - metabolism |
2 |
|
carcinoma, hepatocellular - genetics - immunology - pathology |
2 |
|
carcinoma, hepatocellular - genetics - virology |
2 |
|
carcinoma, hepatocellular - immunology - mortality - pathology |
2 |
|
carcinoma, hepatocellular - metabolism - pathology - therapy |
2 |
|
carcinoma, hepatocellular - mortality - pathology |
2 |
|
carcinoma, hepatocellular - mortality - pathology - surgery - virology |
2 |
|
carcinoma, hepatocellular - mortality - pathology - ultrastructure |
2 |
|
carcinoma, hepatocellular - pathology - secondary - surgery |
2 |
|
carcinoma, squamous cell - drug therapy - genetics - radiotherapy |
2 |
|
carcinoma, squamous cell - pathology |
2 |
|
caspases - genetics |
2 |
|
catalysis |
2 |
|
cci-779 |
2 |
|
cdna array |
2 |
|
cell cycle proteins - biosynthesis |
2 |
|
cell division - genetics |
2 |
|
cell growth processes - physiology |
2 |
|
cell nucleus - immunology - ultrastructure |
2 |
|
cell proliferation - drug effects |
2 |
|
cell signalling pathways |
2 |
|
cell transformation |
2 |
|
cell transformation, neoplastic - genetics |
2 |
|
cell transformation, neoplastic - metabolism |
2 |
|
cellular differentiation |
2 |
|
centrosome |
2 |
|
chelation therapy - adverse effects |
2 |
|
chemosensitivity |
2 |
|
chloroform - therapeutic use |
2 |
|
cholangiocarcinoma - mortality - pathology - ultrastructure |
2 |
|
cholestasis, extrahepatic - diagnosis - etiology |
2 |
|
chromosomal instability - genetics |
2 |
|
cimetidine - therapeutic use |
2 |
|
cisplatin - pharmacology |
2 |
|
classification |
2 |
|
clinical trials as topic |
2 |
|
clinicopathologic features |
2 |
|
clinicopathological features |
2 |
|
clinicopathological significance |
2 |
|
clonal ebv |
2 |
|
clonal tumor |
2 |
|
colon |
2 |
|
coma - physiopathology |
2 |
|
combined hepatocellular- cholangiocarcinoma |
2 |
|
combined therapy |
2 |
|
common bile duct neoplasms - metabolism - pathology - virology |
2 |
|
cten |
2 |
|
cyclin |
2 |
|
cyclin-dependent kinase |
2 |
|
cyclins - metabolism |
2 |
|
cytodiagnosis |
2 |
|
cytomegalovirus infections - complications - diagnosis - epidemiology |
2 |
|
databases, factual |
2 |
|
deferiprone (l1) |
2 |
|
deferoxamine - administration & dosage - adverse effects - therapeutic use |
2 |
|
dendritic cells |
2 |
|
desferrioxamine (dfo) |
2 |
|
differential gene expression |
2 |
|
dipeptidases - genetics - isolation & purification - physiology |
2 |
|
dna damage - physiology |
2 |
|
dna fragmentation |
2 |
|
dna fragmentation - drug effects |
2 |
|
dna methylation - drug effects |
2 |
|
dna modification methylases - antagonists & inhibitors |
2 |
|
dna-binding proteins - antagonists and inhibitors - drug effects |
2 |
|
dox |
2 |
|
drug costs |
2 |
|
drug eruptions - etiology |
2 |
|
drug resistance |
2 |
|
duodenal ulcer - complications - pathology |
2 |
|
efficacy |
2 |
|
egf |
2 |
|
encapsulation |
2 |
|
endothelial cells |
2 |
|
enhancer of zeste homolog 2 (ezh2) |
2 |
|
enucleation |
2 |
|
enzyme phosphorylation |
2 |
|
epigenesis, genetic - drug effects |
2 |
|
epigenesis, genetic - genetics |
2 |
|
epigenetic |
2 |
|
epigenetic-microrna regulatory circuit |
2 |
|
erk1/2 activity |
2 |
|
ethanol - therapeutic use |
2 |
|
feasibility studies |
2 |
|
fever - physiopathology |
2 |
|
fibroblast |
2 |
|
fibrosis - genetics |
2 |
|
fixatives |
2 |
|
fluorescence in situ hybridization |
2 |
|
focal adhesion proteins |
2 |
|
focal adhesions - enzymology - metabolism |
2 |
|
follicular dendritic cell tumor |
2 |
|
follicular dendritic cell tumour |
2 |
|
galactosamine - administration & dosage - economics |
2 |
|
gastritis - drug therapy - etiology - microbiology - pathology |
2 |
|
gastrointestinal diseases - chemically induced |
2 |
|
gastrointestinal diseases - diagnosis - epidemiology - microbiology |
2 |
|
gastrointestinal hemorrhage - etiology |
2 |
|
gene deletion |
2 |
|
gene expression profile |
2 |
|
gene expression regulation, neoplastic - drug effects |
2 |
|
gene rearrangement |
2 |
|
gene set enrichment |
2 |
|
gene signature |
2 |
|
gene silencing - drug effects |
2 |
|
genetic vectors - genetics - pharmacology |
2 |
|
genome-wide screening |
2 |
|
gonadoblastoma gene |
2 |
|
graft occlusion, vascular - prevention & control |
2 |
|
graft vs host disease |
2 |
|
granuloma, plasma cell - pathology |
2 |
|
growth inhibitors - isolation & purification |
2 |
|
gtpase-activating proteins - chemistry - genetics - metabolism |
2 |
|
hbsag |
2 |
|
hbx |
2 |
|
heat exhaustion |
2 |
|
hepatectomy - mortality |
2 |
|
hepatic duct, common |
2 |
|
hepatic progenitor cell |
2 |
|
hepatic progenitor cells |
2 |
|
hepatitis |
2 |
|
hepatitis b surface antigen |
2 |
|
hepatitis b surface antigens - analysis |
2 |
|
hepatitis b virus - metabolism |
2 |
|
hepatitis b virus x protein |
2 |
|
hepatitis c - etiology - therapy |
2 |
|
hepatocellular carcinoma cells |
2 |
|
hepatocellular tumors |
2 |
|
hepatoma |
2 |
|
herpesvirus 4, human - genetics - isolation & purification - physiology |
2 |
|
herpesvirus 4, human - isolation & purification |
2 |
|
high-throughput |
2 |
|
histone deacetylase inhibitors |
2 |
|
histones - metabolism |
2 |
|
homozygote |
2 |
|
human malignancies |
2 |
|
hydrophobic and hydrophilic interactions |
2 |
|
hydroxamic acids - pharmacology |
2 |
|
hypermethylation |
2 |
|
immune milieu |
2 |
|
immunocompromised host |
2 |
|
immunohistochemical |
2 |
|
immunohistochemistry - methods |
2 |
|
immunosuppression |
2 |
|
in silico detection |
2 |
|
in situ nick-end labeling |
2 |
|
inflammatory pseudotumor |
2 |
|
insulin-like growth factor ii |
2 |
|
insulin-like growth factor ii - biosynthesis |
2 |
|
integrin linked kinase |
2 |
|
interactions |
2 |
|
intestinal mucosa - pathology |
2 |
|
intra-abdominal |
2 |
|
intracellular signaling peptides and proteins - antagonists and inhibitors - drug effects - metabolism |
2 |
|
iron chelating agents - administration & dosage - adverse effects - therapeutic use |
2 |
|
iron overload - drug therapy - etiology |
2 |
|
jaundice, obstructive - chemically induced |
2 |
|
ki-67 antigen |
2 |
|
kidney transplantation - adverse effects |
2 |
|
literature review |
2 |
|
liver - cancer - genetic aspects. |
2 |
|
liver - cancer. |
2 |
|
liver - pathology - ultrastructure |
2 |
|
liver -- cancer. |
2 |
|
liver diseases - genetics |
2 |
|
liver diseases - pathology |
2 |
|
liver failure, acute - chemically induced - metabolism - pathology |
2 |
|
liver neoplasms - diagnosis |
2 |
|
liver neoplasms - drug therapy - genetics - metabolism |
2 |
|
liver neoplasms - drug therapy - metabolism |
2 |
|
liver neoplasms - genetics - immunology - pathology |
2 |
|
liver neoplasms - genetics - virology |
2 |
|
liver neoplasms - immunology - mortality - pathology |
2 |
|
liver neoplasms - metabolism - pathology - therapy |
2 |
|
liver neoplasms - mortality - pathology |
2 |
|
liver neoplasms - mortality - pathology - surgery - virology |
2 |
|
liver neoplasms - mortality - pathology - ultrastructure |
2 |
|
liver neoplasms - pathology - radiography |
2 |
|
liver neoplasms, experimental |
2 |
|
liver tumor initiating cells |
2 |
|
mandibular neoplasms - pathology - surgery |
2 |
|
maxillary neoplasms - pathology - surgery |
2 |
|
mib1 |
2 |
|
microfilament proteins - chemistry - genetics - metabolism |
2 |
|
micrornas - genetics - pharmacology |
2 |
|
microsatellite repeats - genetics |
2 |
|
microtubules |
2 |
|
mitogen activated protein kinase |
2 |
|
mouth neoplasms - drug therapy - genetics - radiotherapy |
2 |
|
mtor |
2 |
|
nanog |
2 |
|
nasopharyngeal carcinoma |
2 |
|
nasopharyngeal neoplasms - pathology |
2 |
|
necrosis |
2 |
|
neoplasm metastasis - prevention & control |
2 |
|
neoplasm proteins - analysis |
2 |
|
neoplasm recurrence, local - pathology |
2 |
|
neoplasms, multiple primary - mortality - pathology - ultrastructure |
2 |
|
nerve tissue proteins - biosynthesis - genetics |
2 |
|
nuclear proteins - analysis - genetics |
2 |
|
oncology |
2 |
|
oncovirus |
2 |
|
oral cancers |
2 |
|
p-glycoprotein - analysis |
2 |
|
p-glycoprotein - metabolism |
2 |
|
p21-activated kinases - metabolism |
2 |
|
p53 p21 |
2 |
|
p70s6k |
2 |
|
pathologic features |
2 |
|
pathway analysis |
2 |
|
patient survival |
2 |
|
phosphoric monoester hydrolases - chemistry - genetics - metabolism |
2 |
|
plasma cell |
2 |
|
polyclonal |
2 |
|
polycomb group proteins |
2 |
|
polysaccharopeptide |
2 |
|
portal vein - pathology |
2 |
|
precision oncology |
2 |
|
prognostication |
2 |
|
proliferating cell nuclear antigen - metabolism |
2 |
|
propylthiouracil |
2 |
|
propylthiouracil - administration & dosage - adverse effects |
2 |
|
prostate cancer |
2 |
|
protein biosynthesis |
2 |
|
protein function |
2 |
|
protein-serine-threonine kinases - antagonists and inhibitors - drug effects - metabolism |
2 |
|
proteins - genetics |
2 |
|
proto-oncogene proteins c-bcl-2 - genetics |
2 |
|
proto-oncogene proteins c-jun - drug effects - metabolism |
2 |
|
proto-oncogene proteins c-myc - biosynthesis - genetics |
2 |
|
pyloric antrum - microbiology - pathology |
2 |
|
pyridones - administration & dosage - adverse effects - therapeutic use |
2 |
|
radiation |
2 |
|
random allocation |
2 |
|
rapamycin |
2 |
|
rat |
2 |
|
receptors, antigen, t-cell - genetics |
2 |
|
receptors, estrogen - analysis - biosynthesis |
2 |
|
resection |
2 |
|
retrospective analysis |
2 |
|
rna - analysis |
2 |
|
rna interference |
2 |
|
rna, messenger - genetics |
2 |
|
rna, small interfering - genetics |
2 |
|
rock2 |
2 |
|
scyl3 |
2 |
|
self-renewal |
2 |
|
sex characteristics |
2 |
|
sex chromosomes |
2 |
|
sexual dimorphism |
2 |
|
shock, hemorrhagic - physiopathology |
2 |
|
signal transduction - genetics |
2 |
|
sonic hedgehog |
2 |
|
staining and labeling |
2 |
|
stat3 |
2 |
|
sucralfate - therapeutic use |
2 |
|
survival rates |
2 |
|
swine |
2 |
|
syndrome |
2 |
|
t-cadherin |
2 |
|
tax1bp2 |
2 |
|
tcga |
2 |
|
tetrazolium salts |
2 |
|
thalassemia major |
2 |
|
thiazoles |
2 |
|
thymoma - pathology |
2 |
|
thymus neoplasms - pathology |
2 |
|
thyroid |
2 |
|
thyroid gland |
2 |
|
thyroid neoplasms - pathology |
2 |
|
thyrotoxicosis - drug therapy |
2 |
|
tocotrienol |
2 |
|
tooth, impacted - pathology |
2 |
|
transarterial chemoembolization |
2 |
|
transduction, genetic - methods |
2 |
|
transfection - methods |
2 |
|
treatment response |
2 |
|
truncated hbx |
2 |
|
tspx |
2 |
|
tuberculosis - complications |
2 |
|
tumor encapsulation |
2 |
|
tumor initiating cells |
2 |
|
tumor invasiveness |
2 |
|
tumor suppressor protein p53 - analysis |
2 |
|
tumor suppressor protein p53 - genetics - metabolism |
2 |
|
tumor suppressor proteins |
2 |
|
tumour growth |
2 |
|
tumour suppression |
2 |
|
underexpression |
2 |
|
unicystic ameloblastoma |
2 |
|
vascular neoplasms - secondary - surgery |
2 |
|
viral genomic integration |
2 |
|
viral integration |
2 |
|
viral integration site detection |
2 |
|
whole-transcriptome sequencing |
2 |
|
women |
2 |
|
xenograft model antitumor assays |
2 |
|
3' untranslated regions |
1 |
|
actinomycosis - complications - diagnosis |
1 |
|
actins - genetics |
1 |
|
adenocarcinoma |
1 |
|
adenocarcinoma - chemistry - mortality - pathology |
1 |
|
adenocarcinoma - mortality - pathology - surgery |
1 |
|
adenocarcinoma - pathology - secondary - surgery |
1 |
|
adenoma, pleomorphic - metabolism - pathology |
1 |
|
adrenal gland |
1 |
|
adrenal gland neoplasms - pathology - surgery |
1 |
|
adrenal glands - pathology |
1 |
|
adrenalectomy |
1 |
|
adriamycin |
1 |
|
allelic imbalance |
1 |
|
angiodysplasia - complications - pathology - surgery |
1 |
|
angiomyolipoma |
1 |
|
angiomyolipoma - complications - diagnosis |
1 |
|
animal cell |
1 |
|
antibodies - analysis |
1 |
|
antigens, cd95 - genetics |
1 |
|
antigens, neoplasm - metabolism |
1 |
|
antigens, nuclear |
1 |
|
asian continental ancestry group |
1 |
|
biological markers |
1 |
|
biology |
1 |
|
biopsy, fine-needle |
1 |
|
bone neoplasms - secondary |
1 |
|
breast neoplasms - pathology - surgery |
1 |
|
campylobacter - drug effects |
1 |
|
campylobacter infections - drug therapy - pathology |
1 |
|
cancer immunobiology |
1 |
|
cancer risk |
1 |
|
carcinoembryonic antigen - analysis - blood |
1 |
|
carcinoembryonic antigen - immunology |
1 |
|
carcinoma - pathology - virology |
1 |
|
carcinoma cell |
1 |
|
carcinoma, hepatocellular - chemistry - pathology |
1 |
|
carcinoma, hepatocellular - diagnosis - virology |
1 |
|
carcinoma, hepatocellular - enzymology - pathology - virology |
1 |
|
carcinoma, hepatocellular - genetics - mortality - pathology |
1 |
|
carcinoma, hepatocellular - metabolism - mortality - pathology - surgery |
1 |
|
carcinoma, hepatocellular - pathology - secondary |
1 |
|
carcinoma, squamous cell - ethnology - genetics - pathology |
1 |
|
carcinoma, squamous cell - genetics |
1 |
|
carcinoma, squamous cell - genetics - metabolism - pathology |
1 |
|
carcinoma, squamous cell - metabolism |
1 |
|
carcinoma, squamous cell - pathology - virology |
1 |
|
cell adhesion molecules - metabolism |
1 |
|
cell cycle proteins - genetics - metabolism |
1 |
|
cell cycle regulatory proteins |
1 |
|
cell cycle-related protein |
1 |
|
cell invasion |
1 |
|
cell migration |
1 |
|
checkpoint |
1 |
|
cholangiocarcinoma - chemistry - pathology |
1 |
|
chromosomes, human, pair 9 - genetics |
1 |
|
cisplatin - toxicity |
1 |
|
cluster analysis |
1 |
|
colitis, ulcerative - complications - drug therapy |
1 |
|
colon - metabolism |
1 |
|
colon - pathology |
1 |
|
colonic diseases - chemically induced - epidemiology |
1 |
|
colorectal |
1 |
|
colorectal neoplasms - chemistry - mortality - pathology |
1 |
|
continental population groups |
1 |
|
ct |
1 |
|
cyclin-dependent kinases - antagonists & inhibitors |
1 |
|
cyclins - biosynthesis |
1 |
|
cyclins - genetics |
1 |
|
cyclins - genetics - metabolism |
1 |
|
cytokeratin |
1 |
|
cytomegalovirus infections - complications |
1 |
|
data sets |
1 |
|
death, sudden - etiology |
1 |
|
death, sudden - pathology |
1 |
|
delta-5 desaturase |
1 |
|
delta-6 desaturase |
1 |
|
dementia - metabolism - pathology |
1 |
|
diabetes mellitus |
1 |
|
diabetes mellitus, adult-onset |
1 |
|
diagnosis |
1 |
|
diagnostic criteria |
1 |
|
dilatation, pathologic - complications |
1 |
|
dna content |
1 |
|
dna damage |
1 |
|
dna ploidy |
1 |
|
dna replication |
1 |
|
duodenal ulcer - drug therapy - microbiology - pathology |
1 |
|
dysgerminoma - complications - pathology |
1 |
|
epilepsies, myoclonic - pathology |
1 |
|
expression |
1 |
|
facial bones - pathology - radiography |
1 |
|
fatty liver; liver |
1 |
|
fine‐needle aspiration |
1 |
|
focal infection, dental - complications |
1 |
|
frozen sections |
1 |
|
gastric antral vascular ectasia |
1 |
|
gastric mucosa - microbiology - pathology |
1 |
|
gastric mucosa - pathology |
1 |
|
gastroscopy |
1 |
|
gene frequency |
1 |
|
genes, cdc |
1 |
|
grading |
1 |
|
ground‐glass hepatocytes |
1 |
|
hdac |
1 |
|
head and neck carcinoma |
1 |
|
hemangioma - pathology |
1 |
|
hep3b |
1 |
|
hepatic veno-occlusive disease - metabolism - pathology |
1 |
|
hepatitis b - metabolism |
1 |
|
hepatitis b, chronic - genetics - pathology |
1 |
|
hepatocellular ballooning |
1 |
|
hepatocytes - pathology |
1 |
|
hepatology |
1 |
|
hepatoma cell |
1 |
|
hepatoma cells |
1 |
|
heterozygote |
1 |
|
histamine h2 antagonists - therapeutic use |
1 |
|
histiocytosis, langerhans-cell - complications - pathology |
1 |
|
histocytochemistry |
1 |
|
homeodomain proteins - metabolism |
1 |
|
hong kong - ethnology |
1 |
|
immunoregulation |
1 |
|
inclusion bodies - pathology - ultrastructure |
1 |
|
inherited polymorphism |
1 |
|
intestinal mucosa - metabolism |
1 |
|
intrahepatic |
1 |
|
jaw cysts - radiography - surgery |
1 |
|
keratin-19 - immunology |
1 |
|
keratin-7 - immunology |
1 |
|
keratins - analysis |
1 |
|
keywords |
1 |
|
ki 67 |
1 |
|
ki-67 |
1 |
|
ki-67 antigen - biosynthesis |
1 |
|
kinetics |
1 |
|
kruppel-like transcription factors - metabolism |
1 |
|
lafora bodies |
1 |
|
langerhans' cell histiocytosis |
1 |
|
laser coagulation |
1 |
|
laser therapy |
1 |
|
lipoma |
1 |
|
lipoma - pathology |
1 |
|
lipoma - pathology - surgery |
1 |
|
liver - metabolism - pathology - ultrastructure |
1 |
|
liver - pathology - radiography |
1 |
|
liver cirrhosis - genetics - pathology |
1 |
|
liver diseases - complications - diagnosis |
1 |
|
liver neoplasms - chemistry - pathology |
1 |
|
liver neoplasms - complications - diagnosis |
1 |
|
liver neoplasms - diagnosis - etiology |
1 |
|
liver neoplasms - diagnosis - virology |
1 |
|
liver neoplasms - enzymology - pathology - virology |
1 |
|
liver neoplasms - metabolism - mortality - pathology - surgery |
1 |
|
liver neoplasms - metabolism - virology |
1 |
|
liver neoplasms - pathology - secondary - surgery |
1 |
|
liver transplantation - mortality - pathology |
1 |
|
loss of heterozygosity - genetics |
1 |
|
lymphangioma - pathology |
1 |
|
lymphatic metastasis - diagnosis |
1 |
|
lymphoepithelioma-like carcinoma |
1 |
|
magnetic resonance imaging - methods |
1 |
|
malacoplakia |
1 |
|
malacoplakia - chemically induced - epidemiology |
1 |
|
malignant germ cell tumour |
1 |
|
mandible - radiography - surgery |
1 |
|
mandibular diseases - etiology |
1 |
|
mandibular diseases - pathology - radiography - therapy |
1 |
|
mandibular diseases - radiography - surgery |
1 |
|
matrix metalloproteinase 10 - metabolism |
1 |
|
matrix metalloproteinase 2 |
1 |
|
maxillary diseases - pathology - radiography - therapy |
1 |
|
mdm2 |
1 |
|
medical oncology - standards |
1 |
|
mendelian randomization |
1 |
|
mesocolon |
1 |
|
mesocolon - pathology |
1 |
|
metaplasia - pathology |
1 |
|
metastatic hepatocellular carcinom |
1 |
|
micrornas - antagonists and inhibitors - metabolism |
1 |
|
microsatellite instability |
1 |
|
microscopy |
1 |
|
mir-373 |
1 |
|
molar, third |
1 |
|
mouth |
1 |
|
mouth neoplasms - ethnology - genetics - pathology |
1 |
|
mouth neoplasms - genetics |
1 |
|
mouth neoplasms - genetics - metabolism - pathology |
1 |
|
mouth neoplasms - metabolism |
1 |
|
msin3a |
1 |
|
neoplasm invasiveness - pathology |
1 |
|
neoplasms - metabolism |
1 |
|
neoplasms, multiple primary - pathology - surgery |
1 |
|
neoplasms, squamous cell - metabolism - pathology |
1 |
|
neoplastic stem cells - cytology |
1 |
|
nontumorous liver |
1 |
|
normal dna |
1 |
|
nuclear proteins |
1 |
|
nuclear proteins - metabolism |
1 |
|
octamer transcription factor-3 - metabolism |
1 |
|
omega 3 |
1 |
|
omega 6 |
1 |
|
oral cancer |
1 |
|
oral squamous cell carcinoma |
1 |
|
orbital diseases - pathology - radiography - therapy |
1 |
|
osteolysis, essential - pathology - radiography - therapy |
1 |
|
osteomyelitis - complications - diagnosis - etiology |
1 |
|
ovarian neoplasms - complications - pathology |
1 |
|
o‐acetylation |
1 |
|
p21 |
1 |
|
p21(waf1/cip1) |
1 |
|
p21waf1/cip1 |
1 |
|
p27 |
1 |
|
palatal neoplasms - metabolism - pathology |
1 |
|
papillary |
1 |
|
parenteral nutrition, total |
1 |
|
pathologic prognostic factors |
1 |
|
pathological prognostic indicators |
1 |
|
perihilar |
1 |
|
periodic acid-schiff reaction |
1 |
|
periostitis - complications - diagnosis - etiology - pathology |
1 |
|
peritoneal neoplasms - pathology |
1 |
|
physician's role |
1 |
|
pleomorphic adenoma |
1 |
|
ploidies |
1 |
|
polymerase chain reaction - methods |
1 |
|
polymorphism, genetic |
1 |
|
polyunsaturated fatty acids |
1 |
|
prb |
1 |
|
precancerous conditions |
1 |
|
prednisolone - adverse effects - therapeutic use |
1 |
|
prognosis. |
1 |
|
proliferating cell nuclear antigen - biosynthesis |
1 |
|
proliferation |
1 |
|
proliferation indices |
1 |
|
protein kinases - physiology |
1 |
|
protein-serine-threonine kinases - physiology |
1 |
|
proto-oncogene proteins c-akt - physiology |
1 |
|
proto-oncogene proteins c-mdm2 |
1 |
|
protocols |
1 |
|
pulmonary embolism - complications |
1 |
|
pulmonary tumor embolism |
1 |
|
pyloric antrum - blood supply - pathology |
1 |
|
radiography, dental |
1 |
|
radiography, panoramic |
1 |
|
ranitidine - therapeutic use |
1 |
|
rare diseases |
1 |
|
receptors, estrogen - biosynthesis |
1 |
|
receptors, progesterone - biosynthesis |
1 |
|
rectal carcinomas |
1 |
|
rectal neoplasms - mortality - pathology - surgery |
1 |
|
rectal neoplasms - pathology - surgery |
1 |
|
reproducibility of results |
1 |
|
retinoblastoma protein |
1 |
|
retinoblastoma protein - metabolism |
1 |
|
rna processing |
1 |
|
rna, neoplasm - analysis |
1 |
|
sialic acid |
1 |
|
sialoglycoproteins - genetics - metabolism |
1 |
|
smoking - adverse effects |
1 |
|
snail-1 |
1 |
|
sonography |
1 |
|
sp1 transcription factor - physiology |
1 |
|
squamous metaplasia |
1 |
|
staging |
1 |
|
surgical clearance |
1 |
|
tetrazolium salts - pharmacology |
1 |
|
thiazoles - pharmacology |
1 |
|
thyroid gland - pathology - virology |
1 |
|
tissue and plasma cea |
1 |
|
tomography, x-ray computed - methods |
1 |
|
tongue neoplasms - metabolism |
1 |
|
tooth, unerupted - complications |
1 |
|
trans-activators - genetics - metabolism |
1 |
|
transplantation |
1 |
|
tuberous sclerosis |
1 |
|
tuberous sclerosis - complications |
1 |
|
tumor suppressor protein p53 - analysis - biosynthesis |
1 |
|
tumour |
1 |
|
ulcerative colitis |
1 |
|
vena cava, inferior - pathology |
1 |
|
vesicles. |
1 |
